The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

When would you favor haploidentical HSCT in ALL?

During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the ALL Hub spoke to Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, When would you favor haploidentical HSCT in ALL?

When would you favor haploidentical HSCT in ALL?

In this video, Nagler outlines the types of patients with acute lymphoblastic leukemia (ALL) who would benefit from haploidentical hematopoietic stem cell transplantation (HSCT) over unrelated and/or sibling donor transplantation.

 

Share:
More about...